Uncategorized
Terns sold to Merck for 13% lower than pharma’s initial offer because of clinical data
Although Merck and Terns Pharmaceuticals are part of biotech’s M&A surge, the $6.7 billion deal didn’t nearly play out the way either anticipated.
Merck decided to significantly lower its offer for the …